Small Cap Voice

Intercept Music Shows Scalable, Sustainable Growth and Investment

The Company's financial statements for the year ended Dec 31, 2021 show strong operational performance and financial position for the core Intercept Music business, which provides record label services to the independent music market. In the context of the continued strong performance of the music industry overall (see below), Intercept Music is ideally positioned for continued and sustainable growth with service offerings that are unparalleled among independent music service companies.

As the proof phase of Intercept Music concludes this month, the Company has seen significant increases across many key performance indicators, and has created an infrastructure to accommodate future growth.

Highlights of the 2021 financial report include:

Increased gross sales more than 70% over previous year;

Grew per-artist revenue by 22% over 2020;

Converted more than 75% of short-term convertible debt into long debt and equity;

Raised more than $1.1 million in new equity financing.

Additionally, the Company has expanded and refined its service offerings, with positive results including:

Increased customer base, to a current total of 40 independent labels and 300 independent artists;

Added branded, turnkey online merchandising stores to enhance artist revenue;

Expanded artist marketing services to include playlisting, public relations, advertising, reviews, physical recordings, and more.

Operationally, the Company has created a roadmap for future growth and enhanced profitability, as well. Highlights of this side of the business include:

Streamlined customer service support, resulting in a 50% decrease in customer service requests;

Focused business on labels. As a result of testing initiatives, the Company discovered that compared to individual artists, label customers offer multiple artists, enhanced operational efficiency, and greater resources, among other benefits;

Hired a full-time marketing director, as well as additional customer service and marketing personnel, overall tripling staff count;

Signed with top-end, outsourced service providers to deliver world-class results in software development, public relations, and investor relations, without additional personnel overhead costs.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O’Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT), to discuss how the Company is utilizing artificial intelligence (AI) and other technologies to deliver healthcare to remote areas of Africa.

Xcelerate is an innovation and development company that marries non-medical engineering, advancements and systems with MedTech and clinical care within the healthcare industry. Speaking with SCV’s Stuart Smith, O’Shea explains Xcelerate’s plan to use AI to give the people of Tanzania, Africa, greater access to physicians and medical care.

“The software-based system was originally developed by the folks that develop the AI for self-driving cars and we've applied that to a medical use in an essence. This program allows people in remote areas to reach healthcare professionals by the use of any mobile device. It then builds a database on these people. Facial recognition, if they're a returning patient, allows them to input basic triage information and give the physician a head start on being able to treat the patient prescribed medications,” he says. “We expect that we'll have a beta site for the project launched by end of second quarter and expect to be generating revenues before the end of this year. Additionally, we're filing one patent, hopefully in the next week and three others to follow all based on our initial license, but to be used in surgical instruments and retrofitting them to existing surgical, surgical wounds.”

The interview also highlights the unique expertise of the Xcelerate team, along with several corporate milestones that are moving the Company toward uplisting to the OTCQB and reaching other corporate objectives.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Business Warrior Corp. (OTC: BZWR) (“the Company”) to discuss the Company’s new $25M funding partnership with Fuel Me, the status of the acquisition of the award-winning marketing agency and an updated timeline for the completion of the Company audit for up-listing to the OTC.QB.

Business Warrior is a SaaS company providing small businesses in the United States with a suite of data driven marketing and next-generation, funding solutions to boost local market domination. Founded in 2014, Business Warrior is singularly focused on offering locally targeted lead generation marketing and funding solutions that fuel small business growth. By using next generation machine-learning and native software, Business Warrior has made growth funding and conversion marketing accessible for thousands of under-resourced and under-funded small business owners. For more information, visit BusinessWarrior.com.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO and Giuseppe Del Priore, MD, MPH, the Company's Chief Medical Officer (CMO)of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the Company goals moving forward relating to its current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s checkpoint inhibitors, retifanlimab and epacadostat in advanced breast cancer.

In February 2022, the Company announced the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO).

Dr. Del Priore is a seasoned healthcare executive with over 25 years of experience in research, drug development, and clinical trials management. Dr. Del Priore’s prior work experience includes serving as a biotech Chief Medical Officer, a National Director at the Cancer Treatment Centers of America (CTCA), plus faculty at Indiana University School of Medicine, Weill Cornell Medicine, and New York University School of Medicine.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

Over 80% of Americans snack regularly at night, resulting in an estimated 700 million nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion. The most popular choices are ice cream, cookies, chips, and candy. Recent research confirms such snacks, in addition to being generally unhealthy, can impair sleep, partly due to excess fat and sugar consumed before bed.

Nightfood’s sleep-friendly snacks are formulated by sleep and nutrition experts to contain less of those sleep-disruptive ingredients, along with a focus on ingredients and nutrients that research suggests can support nighttime relaxation and better sleep quality.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the Company”), to discuss how the Company’ is raising the standards for precancerous screening of esophageal cancer.

Stella Diagnostics is developing diagnostic tools that help physicians determine a patient’s risk of disease progression in precancerous indications such as Barrett’s esophagus. Barrett’s is most often diagnosed in people with gastroesophageal reflux disease (GERD or chronic heartburn), which affects over 60 million Americans (one in four adults) and is the only known precursor of esophageal adenocarcinoma (cancer).

The full interview can be heard at: https://www.smallcapvoice.com/interview-stella-diagnostics-sldx/.

Speaking with SCV’s Stuart Smith, Dr. Abdo explains how Stella Diagnostics’ assays quantify the presence of good or harmful protein within biopsy tissue and enhance the current standard of care for Barrett’s screening by providing robust molecular information on the hallmarks of cancer development.

“When we analyze precancerous tissue, we can inform physicians if that tissue is actually possessive of a carcinogenic molecular properties,” he says. “The screening protocol assesses the cell structure, cell organization, cell differentiation of biopsies retrieved during endoscopies. There's very little if any molecular information that's being retrieved with the current standard screening for people that have precancerous diseases like Barrett's esophagus.”

Esophageal cancer is the fastest-rising, deadliest cancer in the United States. Early detection of the disease can significantly increase a patient’s survival rate and quality of life, though current routine screening generally catches esophageal cancers in the advanced stages.

“Our goal at Stella Diagnostics is to have 100% of patients that progress from this precancerous present to their oncologist in stage one or stage zero, where they can actually be cured and not succumb to this very deadly disease,” Dr. Abdo says.

A two-time cancer survivor himself, Dr. Abdo then shares an anecdotal conversation that highlighted the gap between routine screenings and late-stage cancer diagnoses and led to the founding of Stella Diagnostics in 2020.

The goal of the Company’s diagnostic approach is not to replace standard screening protocols, but to rapidly, cost effectively and non-invasively provide superior molecular information that optimizes patient management strategies and leads to earlier detection.

“We want to be used in concert and be a complimentary tool kit for these clinicians to basically make a better-informed clinical decision,” he tells SCV. “When we designed our test, we decided to use a mass spectroscopy because it's very sensitive or requires very little tissue material. … if we can get the right people in the higher risk bucket, then we think that we can ultimately extend and save lives because they would presumably be presenting to their oncologists in the earlier stages.”

Next, the interview highlights various investment considerations, including the expertise of Stella Diagnostics’ board of directors and executive and research and development teams.

“Stella Diagnostics has a deep bench of experience - biotechnology, asset managers, executive leaders - with decades of experience managing and investing in life science organizations,” says Dr. Abdo, who has more than a decade of experience researching molecular oncology mechanisms in gastrointestinal diseases.

“They're doing a great job working to position Stella as a standard screening tool for precancerous diseases. … From the regulatory and biotech leadership aspects, and the asset management aspects, all the way through our clinical science and how we're validating and optimizing our tests with the leading medical institutions in the country, I couldn't be happier with the team that we currently have.”

This expertise is particularly weighty when you consider the competitive advantage it gives to Stella Diagnostics over its competitors.

“We are above and beyond what the standard of care is because we're using multiplexable and high throughput mass spectrometry, which is really dependable and yields very high confident yielding proteomic expression reports with rapid turnaround times,” Dr. Abdo says in describing why the Company’s assays trump the method of genomics and histopathology used by other companies.

“We require the least amount of tissue and report on the most molecular disease drivers. So, there is competition, but we're going to have no problem making a case that our test will be the best for this embattled cohort of patients.”

Stella Diagnostics has multiple collaborative research agreements with leading institutions around the U.S., including Mayo Clinic. For more information on this collaboration and Stella Diagnostics’ technology, SCV points listeners to the Company’s investor page at https://www.stelladx.com/investors/investor-deck-and-news.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Cannabis Global Inc. (OTC Pink: CBGL) to discuss the Company’s rapid growth and competitive advantages in the cannabis market.

Speaking with SCV’s Stuart Smith, Cannabis Global CEO Arman Tabatabaei dives into the Company’s financial performance and expectations for the current quarter.

“We're pretty proud of the way we've been able to conduct business over the past couple of quarters, as it's very clear that we're growing at a very good pace,” he says, referencing strong growth in revenues and total assets.

The interview also highlights the new products and strategies that lend weight to Cannabis Global’s position as a competitive cannabis innovator.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

USTIN, Texas (January 25, 2022) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with technology company IIOT-OXYS, Inc. (OTC : ITOX) (“the Company”) to discuss its operations, recent milestones and outlook for 2022.

Speaking with SCV’s Stuart Smith, IIOT-OXYS, Inc. CEO Cliff Emmons describes the Company’s operations and use of machine learning and proprietary algorithms to provide actionable mission critical insights for clients in a wide range of industries. Despite headwinds of the COVID pandemic, IIOT-OXYS, Inc. was able to adjust its footing and hit key growth catalysts that support its core mission.

“When we take a look at what we've been able to accomplish in 2021, it's very foundational,” Emmons says. “This was the year we found the right financing partners to back the Company so that we could be fully positioned to grow. Secondly, … we have definitely been able to take the additional time that we've had since some foundational proof of concepts were created to further develop our algorithms, sharpen them up, and also use the results and develop them into excellent use cases that we can use as marketing collateral to go out and engage potential customers.”

The discussion also highlights the Company’s performance in 2021 and how its pivot into supply chains and smart manufacturing fits into future plans.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Right on Brands, Inc. (OTC PINK: RTON), a fully reporting SEC filer and developer of a broad line of hemp-based smokables, beverages, tinctures, and topical products including products infused with CBD, Delta-8, Delta-10, THCV, CBDV, THC and Delta-9 (below the federal limit), to discuss the Company’s cutting-edge products in the health and wellness space, the drivers behind the Company’s success to date and goals for 2022.

About ENDO Brands:

ENDO Brands™, Humbly Hemp®, and ENDO Dispensary & Wellness™ All share the same goal of providing our customers with the best products in the health and wellness space. As the field of health and wellness products expand, Right on Brands will be there with industry-leading Food and Beverage and wellness Products.

About Right on Brands:

Right On Brands, Inc., (OTC Pink: RTON) is a Dallas based, consumer goods company specializing in the brand development and distribution of hemp-based foods, beverages, smokables, oils and topical products.

To learn more, please visit: https://www.EndoBrands.com

E-email Inquiries: [email protected]

Corporate Sales: Mike Brown (214) 736-7252

ENDO Brands Corporate Store:

6501 Dalrock Road

Suite 100

Rowlett, Texas 75089

214-299-9528

Austin Licensed Location:

12412 Limerick Avenue (at the corner of Limerick and Parmer Lane_

Austin, Texas 75087

www.endoofaustin.com

512-621-0649

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with American Premium Water Corporation (OTC: HIPH) (the “Company”), a diversified luxury consumer products company focused on businesses in the health, beauty and biotech sectors to discuss the Company’s recent news, the moves made in 2021 and the focus for 2022.

American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health, beauty and biotech sectors. The company is focused on harnessing the powers of Nano technologies paired without cannabidiol (CBD) to treat health disorders and enhance quality of life. The company’s portfolio includes CaliBear (www.calibearlife.com) Vanexxe (www.vanexxe.com) plant + body essentials (www.plantbodyessentials.co).

Shareholders and interested parties are encouraged to follow the Company’s Twitter account @AmericanPremium and CEO Ryan Fishoff @RyanFishoff on Twitter for future Company updates, which will include material information about the Company.